奈米藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按形態、應用、地區和競爭格局分類，2020-2030年預測

2024年全球奈米藥物市場規模為596.8億美元，預計到2030年將以9.80%的複合年成長率成長至1045.8億美元。奈米藥物是一類利用奈米技術增強治療藥物傳遞、標靶性和療效的藥物，通常以奈米級（1至100奈米）製備，以提高藥物的溶解度、穩定性和生物利用度。市場擴張的主要促進因素是慢性疾病盛行率的不斷上升，對標靶性和更有效的治療方案的需求日益成長，以及政府和私人機構對再生醫學和奈米技術藥物研發投入的不斷增加。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球奈米藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依形態分類（脂質體、聚合物膠束、固體脂質奈米顆粒、微乳液、奈米乳液、奈米懸浮液、其他）
  • 依應用領域（臨床腫瘤學、傳染病學、心血管疾病）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美奈米藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲奈米藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太奈米藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲奈米藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲奈米藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球奈米藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Abbott Laboratories Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Johnson & Johnson (J&J)
• Gilead Sciences, Inc.
• AstraZeneca plc
• Celgene Corporation

第16章：策略建議

第17章調查會社について,免責事項

The Global Nanopharmaceuticals Market, valued at USD 59.68 Billion in 2024, is projected to experience a CAGR of 9.80% to reach USD 104.58 Billion by 2030. Nanopharmaceuticals are a class of pharmaceutical drugs leveraging nanotechnology for enhanced therapeutic agent delivery, targeting, and efficacy, typically formulated at the nanoscale (1 to 100 nanometers) to improve solubility, stability, and bioavailability. The market's expansion is primarily driven by the increasing prevalence of chronic diseases demanding targeted and more effective treatment options, coupled with growing government and private funding in regenerative medicine and nanotechnology-based drug development.

Key Market Drivers

The rising prevalence of chronic diseases represents a profound market driver, fueling an urgent demand for advanced therapeutic solutions that surpass the limitations of conventional treatments. Global health challenges posed by conditions such as cancer, cardiovascular ailments, and neurological disorders necessitate therapies offering enhanced efficacy and reduced systemic burden. Nanopharmaceuticals directly address this need through targeted delivery and improved bioavailability, promising better patient outcomes.

Key Market Challenges

The nanopharmaceuticals market faces significant impediment from the high investments required for drug development and the complexities surrounding regulatory approvals for novel nanoscale therapeutics. These factors collectively contribute to prolonged development timelines and substantially increased costs, directly impeding widespread market adoption and commercialization. Developing nanopharmaceuticals demands extensive research and development to understand novel material properties, ensure safety, and demonstrate efficacy at the nanoscale.

Key Market Trends

The focus on personalized nanomedicine is driving advancements by tailoring treatments to individual patient profiles, moving beyond a one-size-fits-all approach. This customization allows for optimized therapeutic effects and reduced adverse reactions, particularly critical for complex diseases. For instance, according to Precision Nanomedicine for Cancer: Innovations, Strategies, and Translational Challenges, published October 2025, the formulation of anti-EpCAM aptamers has risen as an advanced tactic for precise conveyance of therapeutics to malignant tissues, demonstrating significant potential in preliminary research and clinical trials. This capability enhances treatment efficacy and patient outcomes by ensuring therapeutic agents are delivered with high specificity.

Key Market Players

• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Abbott Laboratories Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Johnson & Johnson (J&J)
• Gilead Sciences, Inc.
• AstraZeneca plc
• Celgene Corporation

Report Scope:

In this report, the Global Nanopharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanopharmaceuticals Market, By Form:

• Liposomes
• Polymeric Micelles
• Solid Lipid Nanoparticles
• Microemulsion
• Nanoemulsion
• Nanosuspension
• Others

Nanopharmaceuticals Market, By Application:

• Clinical Oncology
• Infectious Diseases
• Cardiovascular Diseases

Nanopharmaceuticals Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nanopharmaceuticals Market.

Available Customizations:

Global Nanopharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanopharmaceuticals Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension, Others)
  • 5.2.2. By Application (Clinical Oncology, Infectious Diseases, Cardiovascular Diseases)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Nanopharmaceuticals Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Form
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nanopharmaceuticals Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Form
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Nanopharmaceuticals Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Form
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Nanopharmaceuticals Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Form
      • 6.3.3.2.2. By Application

7. Europe Nanopharmaceuticals Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Form
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nanopharmaceuticals Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Form
      • 7.3.1.2.2. By Application
  • 7.3.2. France Nanopharmaceuticals Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Form
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Nanopharmaceuticals Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Form
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Nanopharmaceuticals Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Form
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Nanopharmaceuticals Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Form
      • 7.3.5.2.2. By Application

8. Asia Pacific Nanopharmaceuticals Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Form
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nanopharmaceuticals Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Form
      • 8.3.1.2.2. By Application
  • 8.3.2. India Nanopharmaceuticals Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Form
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Nanopharmaceuticals Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Form
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Nanopharmaceuticals Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Form
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Nanopharmaceuticals Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Form
      • 8.3.5.2.2. By Application

9. Middle East & Africa Nanopharmaceuticals Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Form
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nanopharmaceuticals Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Form
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Nanopharmaceuticals Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Form
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Nanopharmaceuticals Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Form
      • 9.3.3.2.2. By Application

10. South America Nanopharmaceuticals Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Form
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nanopharmaceuticals Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Form
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Nanopharmaceuticals Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Form
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Nanopharmaceuticals Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Form
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nanopharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co., Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Novartis AG
• 15.4. Abbott Laboratories Inc.
• 15.5. GlaxoSmithKline plc
• 15.6. Eli Lilly and Company
• 15.7. Johnson & Johnson (J&J)
• 15.8. Gilead Sciences, Inc.
• 15.9. AstraZeneca plc
• 15.10. Celgene Corporation

16. Strategic Recommendations

17. About Us & Disclaimer